---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053824"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2026-08-06T11:04:40+00:00"
generated_at: "2026-08-06T11:10:12.402932+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics Q2 net loss $8.1M; LCA5 trial enrollment completed

## Summary
- Net loss of $8.1M ($0.08 basic EPS) vs $7.4M loss in Q2 2025; revenue fell to $0.8M from $2.9M.
- Cash and equivalents $88.8M; runway into 2029, excluding potential warrant proceeds or milestones.
- OPGx-BEST1 Cohort 1 topline data expected second week of September 2026.
- OPGx-LCA5 registrational trial enrollment completed; dosing expected Q4 2026 with topline data by end of 2027.
- OPGx-RDH12 enters clinic Q4 2026; OPGx-MERTK clinical testing Q1 2027; OPGx-RHO clinical testing H2 2027.

## SEC filing metadata
- accession: 0001628280-26-053824
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2026-08-06T11:04:40+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/0001628280-26-053824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/ird-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053824
- JSON: https://secwatch.observer/filing/0001628280-26-053824.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.